Brian K. Jefferson, MD, reviews complex recurrent ISR treated w/ the AGENT™ DCB. An AGENT-treated segment remained patent >3 yrs, while a separate adjacent segment treated w/ POBA 13 mos later restenosed within 6 mos.
https://t.co/a6elNbuGyc
When should an interventional cardiologist think beyond the next coronary procedure? Igor Gosev, MD, PhD, discusses earlier advanced HF referral and HeartMate 3 LVAD therapy as part of a lifetime treatment strategy.
https://t.co/L7j7QRhc1K #cardiotwitter
A comprehensive #hypertension program goes beyond any single therapy. Drs. Maria Carolina Delgado-Lelievre and Iliana Hurtado-Rendón discuss individualized evaluation, multidisciplinary care, renal denervation, and long-term follow-up.
https://t.co/3fNChK2O5F #cardiotwitter#RDN
Procedural choices today can affect tomorrow’s HF options. Igor Gosev, MD, PhD, discusses sternum-preserving HeartMate 3 LVAD implantation and how it may fit into a lifetime advanced HF treatment strategy.
https://t.co/rxblZX4xXh #cardiotwitter
From the #AFib Topic Center: Right Internal Jugular Pulsed Field Ablation for Atrial Fibrillation in a Patient With an Inferior Vena Cava Filter
A 77-year-old man with symptomatic AF despite a functioning pacemaker underwent catheter ablation.
Read more: https://t.co/lva5nORdqx
When should an interventional cardiologist think beyond the next coronary procedure? Igor Gosev, MD, PhD, discusses earlier advanced HF referral and HeartMate 3 LVAD therapy as part of a lifetime treatment strategy.
https://t.co/lFZ7jXABtC #cardiotwitter
Creating a New Path for Long, Heavily Calcified Femoropopliteal Occlusions With DETOUR
Drs Zakir and Usman discuss using the DETOUR™ System earlier to bypass complex femoropopliteal occlusions.
https://t.co/wAUcQUQT5q
Kevin Nicholas, MSN, RN, CV-BC, shares how Miami Cardiac and Vascular Institute is expanding cardiovascular care into ASCs, from staffing and workflow to Philips technology and plans for new sites across South Florida.
https://t.co/KN0PMVvMaB
From the #AFib Topic Center: Antithrombotic Therapy and Device Healing After LAAO With WATCHMAN FLX Pro: A Single-Center Real-World Cohort Study
Read more: https://t.co/AzWkUJsM1A #cardiox#cardiotwitter
Why do some ASC startups fall short of expectations? Strategic planning, realistic market and volume assumptions, physician alignment, and operational readiness can make the difference.
https://t.co/zCmoK7IPoG
Build a smarter concomitant LAAC program. Explore how dedicated a high-performing hospital views their AFib workflow as a total program and not just individual procedures.
https://t.co/nQdDrXCX1T